Overview
Addresses the basic and advanced knowledge on psychiatric disorders for non-clinicians
This volume compiles indepth information on the psychopharmacogenetic, representing an important area of research that is based on various specialties including clinical psychiatry, pharmacology, neurobiology and genetics
This book addresses questions related to the field of psychiatric disorders that are not usually addressed in one work making it a tool for a much wider audience than many similar texts.
Includes supplementary material: sn.pub/extras
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (20 chapters)
-
Front Matter
Keywords
About this book
Adult and child psychiatric disorders, including mood disorders, psychosis, substance abuse, and dementia, represent a large source of disability in the general population. The urgency to develop new treatments that may have better efficacy and tolerance is explained by the fact that none of the treatments currently available can be considered completely satisfying. Several reasons underlie this relative failure, such as, for example, (1) lack of knowledge of the mechanisms involved, (2) heterogeneity of most psychiatric disorders (that have good inter-rater validity but weak relationship with specific neurobiological mechanisms), (3) variable tolerance that leads to poor compliance, and (4) insufficient prediction for a specific treated patient of the efficacy, side effects, and outcome associated with the prescribed treatments.
Furthermore, from an economical point of view, psychiatric disorders are now the most expensive disorders to treat. The costs associated with mental illnesses, which constitute a significant percentage of the total direct health care costs, are currently estimated above $100 billion (USD), representing $1,605 per person per year in the U.S. (9% of the gross national product).
Prediction of efficacy, prevention of major side effects, and selection of the most appropriate treatment should thus have major medical and economical impacts. The pharmacogenetics devoted to psychotropic drugs (psychopharmacogenetics) will help to further develop these points.
The psychopharmacogenetic field represents an important area of research that is based on various specialties including clinical psychiatry, pharmacology, neurobiology and genetics. However, data issued from such relevant investigations are frequently, for clinicians as for scientists, rather obscure and/or scattered.
In this book, the basic and advanced knowledge on psychiatric disorders will be provided for non-clinicians: What is schizophrenia? What are the risk factors? What are the core symptoms? How is it treated? What are the efficacy and side effects of the available treatments and their mechanisms? Are there already some psychopharmacogenetic data useful in clinical practice?
Editors and Affiliations
Bibliographic Information
Book Title: Psychopharmacogenetics
Editors: Philip Gorwood, Michel Hamon
DOI: https://doi.org/10.1007/0-387-34577-2
Publisher: Springer New York, NY
eBook Packages: Medicine, Medicine (R0)
Copyright Information: Springer-Verlag US 2006
Hardcover ISBN: 978-0-387-30793-0Published: 12 April 2006
Softcover ISBN: 978-1-4419-4037-7Published: 29 October 2010
eBook ISBN: 978-0-387-34577-2Published: 27 August 2006
Edition Number: 1
Number of Pages: XVI, 566
Number of Illustrations: 58 b/w illustrations
Topics: Psychopharmacology, Neurosciences